Cargando…

Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma

SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma is a rare and aggressive liver tumor that exhibits both hepatocytic and biliary differentiation. In this review we address the recent advances in the genetic and molecular characterization of this tumor and give an overview of possible thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jemmy, Stephan-Falkenau, Susann, Schuler, Markus, Arndt, Börge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913543/
https://www.ncbi.nlm.nih.gov/pubmed/36765942
http://dx.doi.org/10.3390/cancers15030988
_version_ 1784885453099368448
author Zhao, Jemmy
Stephan-Falkenau, Susann
Schuler, Markus
Arndt, Börge
author_facet Zhao, Jemmy
Stephan-Falkenau, Susann
Schuler, Markus
Arndt, Börge
author_sort Zhao, Jemmy
collection PubMed
description SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma is a rare and aggressive liver tumor that exhibits both hepatocytic and biliary differentiation. In this review we address the recent advances in the genetic and molecular characterization of this tumor and give an overview of possible therapeutic implications and systemic and locoregional treatment approaches of this tumor entity. ABSTRACT: Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy that comprises features of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Due to the rarity of this tumor, the treatment of choice has not yet been defined. For resectable disease, liver resection is the mainstay treatment. However, most patients relapse or display advanced disease and were not surgical candidates. Although the majority of patients are either primarily or secondarily treated in palliative intent, no guideline recommendations or prospective trial reports exist to allow reliable evaluation of debated treatment options. We review different locoregional or medical treatment options for advanced combined hepatocellular cholangiocarcinoma (cHCC-CC) in the neoadjuvant, adjuvant, or palliative setting and discuss the possibility of predictive biomarker-guided therapeutic options.
format Online
Article
Text
id pubmed-9913543
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99135432023-02-11 Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma Zhao, Jemmy Stephan-Falkenau, Susann Schuler, Markus Arndt, Börge Cancers (Basel) Review SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma is a rare and aggressive liver tumor that exhibits both hepatocytic and biliary differentiation. In this review we address the recent advances in the genetic and molecular characterization of this tumor and give an overview of possible therapeutic implications and systemic and locoregional treatment approaches of this tumor entity. ABSTRACT: Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy that comprises features of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Due to the rarity of this tumor, the treatment of choice has not yet been defined. For resectable disease, liver resection is the mainstay treatment. However, most patients relapse or display advanced disease and were not surgical candidates. Although the majority of patients are either primarily or secondarily treated in palliative intent, no guideline recommendations or prospective trial reports exist to allow reliable evaluation of debated treatment options. We review different locoregional or medical treatment options for advanced combined hepatocellular cholangiocarcinoma (cHCC-CC) in the neoadjuvant, adjuvant, or palliative setting and discuss the possibility of predictive biomarker-guided therapeutic options. MDPI 2023-02-03 /pmc/articles/PMC9913543/ /pubmed/36765942 http://dx.doi.org/10.3390/cancers15030988 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhao, Jemmy
Stephan-Falkenau, Susann
Schuler, Markus
Arndt, Börge
Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
title Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
title_full Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
title_fullStr Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
title_full_unstemmed Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
title_short Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
title_sort management of locally advanced or metastatic combined hepatocellular cholangiocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913543/
https://www.ncbi.nlm.nih.gov/pubmed/36765942
http://dx.doi.org/10.3390/cancers15030988
work_keys_str_mv AT zhaojemmy managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma
AT stephanfalkenaususann managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma
AT schulermarkus managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma
AT arndtborge managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma